Investment
Features
FeesSafety
Academy
More
Pluang+

Compare F5 Inc (FFIV) vs Cassava Sciences Inc (FLNA) Price & Performance

F5 IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

F5 Inc vs Cassava Sciences Inc — how do they compare? F5 Inc trades at $402.08 (market cap $23.79B), while Cassava Sciences Inc trades at $1.07 (market cap $53.14M). The key difference: F5 Inc is far larger — about 447.7× Cassava Sciences Inc's market cap, and F5 Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FFIVFLNA
Market Cap
$23.79B$53.14M
Sector
TechnologyHealth
52-Week High
$431.26$4.64
52-Week Low
$223.99$1.09
Enterprise Value
$22.60B-$33.43M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

F5 Inc

F5 Networks (FFIV) trades at $419.00, down 2.84% on the day, but remains in a bullish technical trend above key support levels. The company demonstrates strong fundamental momentum with revenue growth to $3.09B in 2025 and consistent earnings beats, including a recent Q1 2026 EPS of $3.90 against a $3.46 expectation. Recent news highlights strategic expansion into AI security, including the acquisition of SurePath AI (GeekWire, 2026-06-26).

The outlook is supported by robust profitability and strategic positioning in application security, but elevated valuation multiples (P/E 34.61, P/S 7.6) and a high current price relative to the analyst consensus target of $397.00 present near-term valuation risk. The primary investment opportunity lies in the company's execution on its AI security platform growth, while risks include competitive pressures and the stock's premium pricing.

Cassava Sciences Inc

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Returns comparison

Trailing returns across standard periods

About F5 Inc

F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.

Read more on FFIV

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA